Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Gains from Investment Securities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Gains from Investment Securities for 11 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 109.25% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $24.2 million for FY2025, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was $5.1 million at BeOne Medicines, down from $9.0 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $175.9 million in Q4 2021, with the low at -$54.8 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $13.0 million, with a median of $7.8 million recorded in 2024.
  • Peak annual rise in Gains from Investment Securities hit 5327.02% in 2023, while the deepest fall reached 999.89% in 2023.
  • Over 5 years, Gains from Investment Securities stood at $175.9 million in 2021, then plummeted by 97.45% to $4.5 million in 2022, then tumbled by 999.89% to -$40.4 million in 2023, then crashed by 35.45% to -$54.8 million in 2024, then surged by 109.25% to $5.1 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $5.1 million, $9.0 million, and -$5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.